DCTH — Delcath Systems, Inc. stock price, charts and financials

Latest market price

16.16

+1.04+6.92%

Overview Short InterestFilings

DCTHQT68Delcath Systems, Inc.·NASDAQ

Overview Short InterestFilings

16.16+6.92%

News

Up 6.9% — Delcath: Temporary Headwinds Are Fading While Larger Opportunities Approach (SeekingAlpha).

Medium confidence

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

VREX+48.43%$18.42 NPCE+0.44%$14.89 CTKB+2.26%$4.29 CERS+3.70%$2.44 KIDS+1.67%$23.15 BWAY-0.90%$15.36 CLPT+2.50%$14.56 OFIX+0.24%$10.31

Snapshot

Index	-	P/E	-	EPS (ttm)	0.01	Insider Own	-	Shs Outstand	34.52M	Perf Week	23.65%

Market Cap	521.62M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.07%	Shs Float	28.60M	Perf Month	11.76%

Enterprise Value	476.56M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	9.42%	Perf Quarter	34.43%

Income	521.62K	P/S	5.47	EPS this Y	-4413.40%	Inst Trans	-	Short Ratio	5.73	Perf Half Y	69.02%

Sales	95.42M	P/B	4.48	EPS next Y	-4.57%	ROA	0.39%	Short Interest	2.69M	Perf YTD	49.60%

Book/sh	-	P/C	26.52	EPS next 5Y	-	ROE	0.46%	52W High	17.51 -7.75%	Perf Year	42.01%

Cash/sh	-	P/FCF	29.31	EPS past 3/5Y	-	ROIC	-0.60%	52W Low	8.68 86.08%	Perf 3Y	277.75%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	204.86% 111.68%	Gross Margin	87.05%	Volatility	7.28% 4.86%	Perf 5Y	48.14%

Dividend TTM	-	EV/Sales	4.99	EPS Y/Y TTM	108.40%	Oper. Margin	-1.90%	ATR (14)	0.78	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	8.95	Sales Y/Y TTM	145.95%	Profit Margin	0.56%	RSI (14)	68.79	Recom	2.36

Dividend Gr. 3/5Y	-	Current Ratio	9.83	EPS Q/Q	-	SMA20	17.98%	Beta	0.56	Target Price	25.33

Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	25.00%	SMA50	22.93%	Rel Volume	2.26	Prev Close	15.11

Employees	156	LT Debt/Eq	0.01	Earnings	Nov 03	SMA200	43.56%	Avg Volume	535.64K	Price	16.16

IPO Date	May 03, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	69.12% 6.34%	Net Debt/EBITDA	-26.58	Volume	1,212,337	Change	6.92%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-07-26	Reiterated	H.C. Wainwright	Buy	$30 → $32
Jul-13-26	Reiterated	BTIG	Buy	$16 → $17
Feb-26-26	Reiterated	Evercore ISI		$27
Feb-26-26	Reiterated	BTIG	Buy	$19
Oct-21-25	Reiterated	Craig-Hallum	Buy	$24 → $20
Oct-20-25	Reiterated	HC Wainwright & Co.	Buy	$24 → $30
Mar-07-25	Reiterated	HC Wainwright & Co.	Buy	$22 → $24
May-15-24	Reiterated	HC Wainwright & Co.	Buy	$22
May-03-13	Downgrade	JMP Securities	Market Outperform → Perform
May-03-13	Downgrade	Wedbush	Outperform → Neutral

Latest News

Aug-07-26

Aug-07-2604:33PM

Delcath: Temporary Headwinds Are Fading While Larger Opportunities ApproachSeekingAlpha

Aug-06-26

Aug-06-2605:14PM

Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcriptseekingalpha.com

12:04PM

Delcath Systems Q2 Earnings Call Highlightsmarketbeat.com

10:51AM

Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimateszacks.com

08:01AM

Delcath Systems Reports Second Quarter 2026 Results and Business Highlightsbusinesswire.com

Jul-28-26

Jul-28-2604:01PM

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conferencebusinesswire.com

Jul-23-26

Jul-23-2604:01PM

Delcath Systems to Host Second Quarter 2026 Earnings Callbusinesswire.com

Jul-16-26

Jul-16-2604:01PM

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com

Jul-09-26

Jul-09-2608:00AM

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancerbusinesswire.com

Company

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	96	85	37	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	13	12	6	—	—	—	—	—	—
Gross Profit	83	73	31	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	47	44	30	—	—	—	—	—	—
Research and Development	37	29	14	—	—	—	—	—	—
Other Operating Expense	1	0	-1	—	—	—	—	—	—
Operating Income	-2	1	-12	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	4	3	-14	—	—	—	—	—	—
Net Income Before Taxes	1	4	-26	—	—	—	—	—	—
Income Taxes	1	1	0	—	—	—	—	—	—
Consolidated Net Income	1	3	-26	—	—	—	—	—	—
Net Income From Continuing Operations	1	3	-26	—	—	—	—	—	—
Net Income	1	3	-26	—	—	—	—	—	—
EPS (Recurring)	0.01	-0.05	-0.11	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.01	-0.05	-0.11	—	—	—	—	—	—
EPS (Diluted)	0.01	-0.05	-0.12	—	—	—	—	—	—
EBITDA	1	4	-26	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	1,615.50	—	—	—	—	—	—	—	—
Price To Sales Ratio	6.06	4.28	9.44	—	—	—	—	—	—
Gross Margin	86.46	85.88	83.78	—	—	—	—	—	—
Operating Margin	-2.08	1.18	-32.43	—	—	—	—	—	—
Net Margin	1.04	3.53	-70.27	—	—	—	—	—	—
Shares Outstanding	36	36	29	—	—	—	—	—	—
Market Capitalization	582	364	349	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pennell Sandra	Chief Financial Officer	Mar 06 '26	Buy	9.04	5,533	50,018	77,018	Mar 06
MICHEL GERARD J	CHIEF EXECUTIVE OFFICER	Mar 02 '26	Buy	8.96	11,200	100,309	342,034	Mar 03
Sylvester John Richard	Director	Nov 21 '25	Buy	8.89	4,386	38,992	14,936	Nov 25
MICHEL GERARD J	CHIEF EXECUTIVE OFFICER	Nov 11 '25	Buy	8.53	11,500	98,049	330,834	Nov 13
Vukovic Vojo	CHIEF MEDICAL OFFICER	Jun 12 '25	Option Exercise	4.78	42,000	200,760	168,882	Jun 13
Aharon Gil	Director	May 05 '25	Option Exercise	10.00	400,000	4,000,000	3,413,468	May 09
SALAMON STEVEN A J	Director	May 05 '25	Option Exercise	10.00	400,000	4,000,000	3,413,468	May 09
Rosalind Advisors, Inc.	Director	May 05 '25	Option Exercise	10.00	400,000	4,000,000	3,413,468	May 09
SALAMON STEVEN A J	Director	Dec 24 '24	Option Exercise	0.01	603,954	6,040	1,323,919	Dec 27
Aharon Gil	Director	Dec 24 '24	Option Exercise	0.01	603,954	6,040	1,323,919	Dec 26
Rosalind Advisors, Inc.	Director	Dec 24 '24	Option Exercise	0.01	603,954	6,040	1,323,919	Dec 26
Aharon Gil	Director	Oct 30 '24	Option Exercise	1000.00	500	500,000	0	Nov 01
SALAMON STEVEN A J	Director	Oct 30 '24	Option Exercise	1000.00	500	500,000	0	Nov 01
Rosalind Advisors, Inc.	Director	Oct 30 '24	Option Exercise	1000.00	500	500,000	0	Nov 01
MICHEL GERARD J	CHIEF EXECUTIVE OFFICER	Oct 22 '24	Option Exercise	6.00	16,666	99,996	319,334	Oct 23

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.